Infuseon Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Cleveland OH United States (2012)
Status: No NME R&D (2012)

Organization Overview

First Clinical Trial
2014
NCT02278510
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Infuseon Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Astrocytoma (Phase 1)

Glioblastoma (Phase 1)

Glioma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 4